asterisk2a + threats   2

Pfizer and AstraZeneca: Deal or no deal | The Economist
IT'S ALL A MATTER OF DEGREE. Degree of vitality, dynamism, plurality & competition further reduced within the pharmaceutical industry in case of a M&A deal. + "M&A deals intended specifically 2 enable growth fail 2 achieve their expressed growth objective." + /// vs. Internal Growth through start-up/entrepreneurial culture within. --->> once you are a public company, your options to facilitate growth are hugely curtailed do to the short-term thinking of money, crony capitalism >> Wall Street. /// + + | BRITISH INTEREST IS & SHOULD BE MARKET PLURALITY. From May 7th. - 7 days later | this case; fiduciary responsibility = short-term thinking
market  plurality  Pfizer  AstraZeneca  UK  big  pharma  pharmaceutical  industry  pharma  oligopol  oligopoly  crony  capitalism  corporate  governance  WallStreet  growth  though  acquisition  M&A  mergers  merger  growth  through  merger  Career  Politicians  business  management  short-term  thinking  long-term  thinking  public  policy  antitrust  Competition  collusion  research  medical  research  public  health  policy  trust  trustagent  confidence  Science  R&D  European  Competition  Commission  Europe  regulators  regulation  governance  transparency  accountability  davidcameron  general  election  2015  GeorgeOsborne  Lobbying  lobbyist  lobby  interest  groups  national  interest  job  market  productivity  skill-biased  technological  change  skill  skills  capital  skills  knowledge  worker  White-collar  Blue-collar  Mobile  Creative  Mobile  Creatives  fiduciary  responsibility  greed  stakeholder  shareholder  unknown  unknowns  unintended  consequences  complexity  human  progress  technological  progress  humanity  post-antibiotic  era  external  threats  externalaties  externality 
may 2014 by asterisk2a

related tags

#GamerGate  &  accountability  acquisition  antitrust  AstraZeneca  big  Blue-collar  bullying  business  capital  capitalism  Career  change  collusion  Commission  Competition  complexity  confidence  consequences  corporate  Creative  Creatives  crony  cyber  davidcameron  death  election  era  Europe  European  external  externalaties  externality  fiduciary  general  GeorgeOsborne  governance  greed  groups  growth  health  human  humanity  industry  interest  job  Justice  knowledge  Law  lobby  Lobbying  lobbyist  long-term  M&A  management  market  medical  merger  mergers  mobbing  Mobile  national  oligopol  oligopoly  online  Pfizer  pharma  pharmaceutical  plurality  policy  Politicians  post-antibiotic  productivity  progress  public  R&D  regulation  regulators  research  responsibility  Science  shareholder  short-term  skill  skill-biased  skills  stakeholder  System  technological  thinking  though  threats  through  transparency  trust  trustagent  UK  unintended  unknown  unknowns  WallStreet  White-collar  worker 

Copy this bookmark: